As expected, the FDA today committed to a six-month priority review with BMS for nivolumab ("Opdivo"), following a similar process as that done with Merck for pembrolizumab ("Keytruda"):
I hope that they do not require people to fail with ipi the way they did with the merck drug. The rate of success with ipi is fairly low, and yet with Keytruda the FDA requires that huge expense before the next huge expense. I do not understand our medical system.
I hope that they do not require people to fail with ipi the way they did with the merck drug. The rate of success with ipi is fairly low, and yet with Keytruda the FDA requires that huge expense before the next huge expense. I do not understand our medical system.
I hope that they do not require people to fail with ipi the way they did with the merck drug. The rate of success with ipi is fairly low, and yet with Keytruda the FDA requires that huge expense before the next huge expense. I do not understand our medical system.
Viewing 2 reply threads
You must be logged in to reply to this topic.
About the MRF Patient Forum
The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.
The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.
.
.
